Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...

Health-care companies fell as traders weighed risks in a wave of deal activity. Pfizer joined Big Pharma rivals hunting for novel weight loss drugs in the Chinese biotech sector.

Jeff Williams, a former Apple executive, will stand for election as a new independent director of Disney at the 2026 annual ...

The executive, who would expand the size of the board to a total of 11 members, will stand election at the media giant's 2026 annual meeting of shareholders ...

Dow Jones Top Company Headlines at 7 PM ET: JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks May Have to Keep Up. | Nvidia ... JPMorgan Stock Sinks on Higher Expense Outlook. Other Banks ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Welcome The Hill’s annual list of Top Lobbyists. President Trump’s return to the White House brought a whirlwind of policy ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Discover a diversified portfolio of ETFs & CEFs for 6%+ income yield, market-matching growth, and lower tech risk.

In our initial taste test, conducted all the way back in 2022, we were simply looking for the best gummy candy in the most ...